Swiss regulator approves first malaria treatment for newborn babies
In a late-stage clinical trial, pharmaceutical giant Novartis showed the drug was safe and effective for babies weighing less than five kilograms, which they typically reach by two months of age.
Traditionally, these infants have been given either a full or half-dose of the antimalarial drug intended for babies six months or older. But because newborns do not process medicines the same way, there is a higher risk of side effects.
The lack of specialised treatment – and the fact that babies are not vaccinated until they are around five months old – has left the youngest infants relatively unprotected against malaria, a mosquito-borne disease that kills about 597,000 people per year.
Most deaths are among children under five years old in Africa.
It's not clear exactly how many babies are affected, but in 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread. About one in three mothers were infected with malaria while pregnant, raising the risk that they will pass the disease along to their newborns, according to the World Health Organization (WHO).
'Every one of those [babies] is a potential target for malaria infection,' Dr Lutz Hegemann, president of Novartis' global health programme, told Euronews Health.
'We don't want to leave any patient behind, no matter how small they are'.
Eight African countries – Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda – are expected to quickly approve the medicine as part of a partnership with Swissmedic, the Swiss drugs regulator.
Hegemann said Novartis hopes to roll the medicine out there this autumn, with more countries to follow, on a not-for-profit basis.
The medicine, known as Coartem Baby, is similar to Novartis' existing drug to treat uncomplicated malaria in young children, but it has a different dose and ratio of ingredients to prevent side effects in the youngest infants.
It also has a sweet cherry flavour and can be dissolved in breast milk to make it easier to give to patients.
'These are small changes, but big steps,' Dr Quique Bassat, head of the Barcelona Institute of Global Health, told Euronews Health.
While the number of newborns with malaria 'still remains relatively modest in terms of the overall burden, those cases need to be treated, and therefore we need better drugs,' he added.
'Now we have something which is perfectly suitable for that specific age group where there was a gap'.
Bassat advised Novartis on the clinical trial, which was funded by the European Union and the Swedish International Development Cooperation Agency.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
4 days ago
- Euronews
Swiss regulator approves first malaria treatment for newborn babies
Switzerland's drug regulator has approved the world's first malaria treatment for newborn babies, clearing the way for the medicine to become available in parts of Africa where the life-threatening disease is endemic. In a late-stage clinical trial, pharmaceutical giant Novartis showed the drug was safe and effective for babies weighing less than five kilograms, which they typically reach by two months of age. Traditionally, these infants have been given either a full or half-dose of the antimalarial drug intended for babies six months or older. But because newborns do not process medicines the same way, there is a higher risk of side effects. The lack of specialised treatment – and the fact that babies are not vaccinated until they are around five months old – has left the youngest infants relatively unprotected against malaria, a mosquito-borne disease that kills about 597,000 people per year. Most deaths are among children under five years old in Africa. It's not clear exactly how many babies are affected, but in 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread. About one in three mothers were infected with malaria while pregnant, raising the risk that they will pass the disease along to their newborns, according to the World Health Organization (WHO). 'Every one of those [babies] is a potential target for malaria infection,' Dr Lutz Hegemann, president of Novartis' global health programme, told Euronews Health. 'We don't want to leave any patient behind, no matter how small they are'. Eight African countries – Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda – are expected to quickly approve the medicine as part of a partnership with Swissmedic, the Swiss drugs regulator. Hegemann said Novartis hopes to roll the medicine out there this autumn, with more countries to follow, on a not-for-profit basis. The medicine, known as Coartem Baby, is similar to Novartis' existing drug to treat uncomplicated malaria in young children, but it has a different dose and ratio of ingredients to prevent side effects in the youngest infants. It also has a sweet cherry flavour and can be dissolved in breast milk to make it easier to give to patients. 'These are small changes, but big steps,' Dr Quique Bassat, head of the Barcelona Institute of Global Health, told Euronews Health. While the number of newborns with malaria 'still remains relatively modest in terms of the overall burden, those cases need to be treated, and therefore we need better drugs,' he added. 'Now we have something which is perfectly suitable for that specific age group where there was a gap'. Bassat advised Novartis on the clinical trial, which was funded by the European Union and the Swedish International Development Cooperation Agency.
Euronews
02-07-2025
- Euronews
Where are you most likely to live to 100 and why?
People who reach their 100th birthdays this year have seen quite a lot. Born in 1925 between two World Wars, they've witnessed the advent of everything from penicillin to TikTok. But very few people have crossed that mark. Worldwide, there are about 630,000 centenarians – people aged 100 or older – and the vast majority live in just 10 countries, according to the latest estimates from the United Nations. These 10 countries span Asia, Europe, and North America, and they run the gamut on size, economic strength, politics, healthcare quality, and social structures. One in five centenarians, or about 123,000 people, live in Japan, which also has one of the world's highest life expectancies at 88 years for women and 82 years for men. It is followed by the United States, which has about 74,000 centenarians, China (around 49,000), and India (38,000). Considering the number of centenarians relative to population size, however, the US and China drop down the list and European countries such as France, Greece, and Italy rise closer to the top. Japan remains exceptional, with 100 centenarians per 100,000 people, behind only Hong Kong, with a rate of 133. 'Japan is at the top of all lists,' Solveig Cunningham, a professor who leads health, ageing and longevity research at the Netherlands Interdisciplinary Demographic Institute, told Euronews Health. That's likely due to a combination of nutrition, exercise, and a healthy 'living environment,' Cunningham said. But the real test would be to track the health of people who immigrated to Japan decades ago, and see if they fare as well as native Japanese people as they age. What drives extreme longevity? Extreme longevity has long puzzled scientists and captivated the public, spawning countless books, TV shows, headlines, and self-help guides. One popular explanation is the theory of 'blue zones,' or geographic regions where people live remarkably long lives due to a combination of healthy diets, active lifestyles, strong social relationships, and genetics. But researchers have also raised questions about whether these 'blue zones' are real, or simply a matter of flawed data. One study made waves last year when it flagged two reasons why some countries appear to have so many centenarians: administrative errors with birth certificates, and fraud in pension and benefit systems. Cunningham said there likely are some 'data aberrations,' but they probably do not account for bigger picture trends, particularly because countries with the most centenarians also tend to have longer life expectancies overall. 'If we think these are places where people generally live longer, it's not surprising that a larger proportion will make it there,' she said. Even countries with lower life expectancies could be home to a surprising number of centenarians. 'In places where you have pretty high mortality early in life, the people who survive are outstandingly strong,' Cunningham said. It doesn't appear that there's a 'magical concoction,' she added. For now, there are still more questions than answers when it comes to extreme longevity, but demographers and health experts say the keys to ageing well are simple: regular exercise, healthy food, access to medical care, getting enough sleep, avoiding alcohol and tobacco, and managing stress. 'I don't know how much I personally would buy into [claims on the benefits of] fish oil and chocolate and a glass of wine,' Cunningham said.
Euronews
01-07-2025
- Euronews
How is a messaging app improving public health in China?
Everyone loves the idea of personalised healthcare, but when it's been trialled in the past, the cost is often too high, both for the pharmaceutical companies producing the drugs and for the patients and healthcare systems. 'That's why the pharma companies like to develop 'blockbusters'. It's just one drug for all,' Dr Alex Ng told Euronews Health. But what if AI could change all that? We sat down with Dr Alex Ng, president of Tencent Healthcare, to hear about the game-changing possibilities of AI in healthcare and living up to the company's motto of 'tech for good'. Access to healthcare Whilst we all know technology can bring some great innovations and development to an industry, Ng is very conscious of the problems a lack of access can create as a service becomes more digitised. 'What we have seen with history is that with digitisation, with more and more machines, you are actually inadvertently widening the inequality gap,' Ng explained. 'A lot of that may be due to access, and a lot will be due to reimbursement, payments, [and] ability to pay. Now, we've seen that with every single wave of technology development, it gets wider and wider'. Tencent is a Chinese technology conglomerate but it is best known for its popular messaging app, WeChat. By leveraging the popularity of the app, Tencent have added extra features to help increase access to healthcare for their users in China. Users can book hospital or clinic appointments, get a tele-consultation and browse health and drug information through their equivalent of WhatsApp. 'We used to write a lot of medical articles to do health education, health awareness. But now, people are going to AI, whether it's actually ChatGPT or chatbots,' Ng said. 'We can make sure that the answer that they get is much more rigid and verified and much more peer-reviewed, versus a lot of the hallucinations that AI can sometimes get'. This is a particularly important service in China, where, Ng explained, patients receive their test results at the same time as a doctor. And like most of us would do too, many patients look to the internet to interpret the results before their follow-up appointment with their doctor. 'A lot of the time, we provide tools against AI to actually explain to them what these test results mean. Of course, with the usual caveat, that we cannot replace the doctor's advice,' he explained. 'Even if we didn't provide a rigorous AI engine to help them with that, they would just do it on any other random AI that is not healthcare specific. If they just go to a random tool and they do it, the hallucination inaccuracy might be even higher. 'And so we come from a vantage point where we are well aware of the seriousness of supporting the patient and the user in interpreting some of the results. So we try to offer a much more ground truth alternative'. Can we accept AI that makes mistakes in healthcare? The results of using AI for the greater good of public health seem obvious but where the debate gets interesting is our capacity to accept mistakes. When working with humans, we appear to be much more accepting of human error, yet expect AI, a human-created technology, not to make any mistakes. 'AI is never perfect. Just like drugs, each drug is intended for a certain indication, but you also accept that it will have side effects and some mild, some moderate, some serious, for the whole population. And there's a regulator, there are laws around to protect that, because otherwise no one will be investing in developing new drugs,' Ng said. 'I think the same for AI. If we have one AI being developed for a specific task, it might be better than humans already, but it is not faultless. If there are certain faults within a boundary, that is acceptable, how do you regulate that? 'How do we, as a health system, work with the regulators, work with health systems in some way, work with society on what is acceptable? And I think that line is very different for China, Southeast Asia, the US, Europe, and the UK because I think the expectation is very different'.
